Mergers & acquisitions
When GSK’s consumer health spinoff Haleon launches later this month, the new business will carry more than $12 billion in debt when it lists on the London Stock Exchange.
Portage Biotech announced Wednesday that it has inked an acquisition agreement with New York-based Tarus Therapeutics, adding four new candidates to its pipeline.
Merck is in late-stage discussions to acquire Seagen for about $40 billion according to a Wall Street Journal report.
As the global life sciences industry slows down, companies are gathering money through means other than VC funding. BioSpace shines a light on some of these recent transactions.
BioSpace caught up with Roland and Ben Buelow of Ancora, and Lightspeed Venture Partners’ Galym Imanbayev to talk about the AstraZeneca deal and the company’s unique business model.
The transaction, expected to close in the third quarter of this year, includes TeneoTwo’s proposed drug for relapsed and refractory B-cell non-Hodgkin lymphoma TNB-486.
This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.
Ipsen announced it is acquiring the company and its cancer drugs, including Tazverik, which were approved for two different indications by the FDA in 2020.
Talks between Merck and Seagen are heating up as the former looks to buy the latter, according to a report published by The Wall Street Journal.
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
PRESS RELEASES